Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exec Chat: Cognetivity’s Simple Brain Test Could Unlock Trillions In Health Care Savings

Executive Summary

Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.

You may also be interested in...



Could Smart Watches And Phone Apps Detect Alzheimer’s Years Before Symptoms Present?

Investigational therapies are finally achieving some success in treating Alzheimer’s disease, but a cure is not yet in sight. Medtech now has a golden opportunity in pre-symptomatic detection, according to digital health tech research initiative, EDoN.

Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.

Finding A Rock ‘n Roll Moment In Dementia Diagnostics

Find a problem and develop the solution for it: so goes the accepted wisdom for successful health care technology adoption. But as Cognetivity Neurosciences CEO Sina Habibi demonstrates, the reverse can also provide a very valid business pathway.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel